Michael Freeman, MB BS, FRACGP, FACD


The Skin Centre
Suite 3.07, Level 3

Pindara Specialist Suites

29 Carrara Street
Benowa, Queensland, Australia
07 5597 7170


Specialty: Dermatology


Dr. Michael Freeman, Dermatologist Specialist in Psoriasis

Research Interests: Actinic Keratoses, Atopic Dermatitis (Eczema), Basal Cell Carcinoma, Melanoma, Onychomycosis, Psoriasis, Rosacea, Squamous Cell Carcinoma


Dr. Michael Freeman began his general medicine practice in Queensland, Australia almost 30 years ago. After a number of years as a general practitioner Dr. Freeman decided to specialize in Dermatology. Since 1995 Dr. Freeman has been practicing at The Skin Centre located in the Gold Coast community.

The Skin Centre, led by Dr. Freeman, has been an investigative site for clinical trials on psoriasis, actinic keratosis, basal cell carcinoma and many other dermatological conditions. The dermatologists and nurses at The Skin Centre participate in clinical trials in order to offer the community with access to new treatments for skin conditions.

Dr. Freeman further supports the community as the Director of Dermatology at the Gold Coast Hospital and he is also a Visiting Medical Officer at the Princess Alexandra Hospital in Brisbane. Along with his involvement in local hospitals, Dr. Freeman is also an Associate Professor of Dermatology at Bond University. Dr. Freeman is also a member of many dermatology groups both nationally and internationally including, Australasian College of Dermatologists, Skin and Cancer Foundation Queensland and the American Academy of Dermatology.

Due to his extensive clinical experience, Dr. Freeman is often invited to lecture on topics in dermatology. In addition Dr. Freeman’s involvement in clinical trials has allowed him to publish many articles in peer-reviewed journals.


Click to view Dr. Michael Freeman's Publications

Adams A, Sharpe KK, Peters P, Freeman M. Hereditary leiomyomatosis and renal cell cancer (HLRCC): cutaneous and renal manifestations requiring a multidisciplinary team approach. BMJ Case Rep 2017 Apr 11. PMID: 28400389 / doi: 10.1136/bcr-2016-215115

Peters P, Sharpe K, Pitney L, Charlston S, Thomas S, Abdel-Malek L, Freeman M. Treatment of diffuse superficial actinic porokeratosis using fluorouracil chemowraps. Australas J Dermatol 2016 May; 57: 67-8.

Freeman A, Freeman MG, Andrews S. A new anatomical landmark for a mental nerve block (MNB), improving the efficacy in edentulous patients. Australas J Dermatol 2016; 57.

Freeman A, Freeman MG. Modified 5-Fluorouracil (5-FU) chemo-wraps for the home management of intraepidermal carcinoma (IEC) and disseminated superficial actinic porokeratosis (DSAP). Australas J Dermatol 2016; 57.

Stevenson P, Freeman M. The efficacy of home based chemo-wraps of topical 5-flurouracil (5-FU) for solar keratoses on the limbs: A case series. Australas J Dermatol 2016; 57.

Thomas S, et al. The sequelae of metallosis resulting in skin pigmentation and tattooing: A full literature review. Australas J Dermatol 2016; 57.

Gabizon S, Freeman M. Statins reduce the risk of melanoma: truth or myth? Australas J Dermatol 2015; 56.

Freeman M, Zibert JR, Knudsen KM, Spelman L, Rosen R. Ingenol mebutate gel topically applied under occlusion to superficial basal cell carcinoma is efficacious compared with marginal effect in seborrheic keratosis. J Am Acad Dermatol 2014 May; 70(5): Suppl 1, AB136. doi: 10.1016/j.jaad.2014.01.567

Spelman L, Rosen R, Knudsen KM, Zibert JR, Freeman M. Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. Br J Dermatol 2014 Sep; 171(3): E71.

Rosen R, Freeman M, Zibert JR, Katsamas J, Knudsen KM, Spelman L. Ingenol mebutate 0.05% gel reduces cancer cells in squamous cell carcinoma in situ and shows marginal effect in seborrhoeic keratosis. Br J Dermatol 2014 Sep; 171(3): E62-3.

Freeman A, Bridge JA, Maruthayanar O, Overgaard NH, Jung JW, Simpson F, Prow TW, Soyer HP, Frazer IH, Freeman M, Wells JW. Comparative immune phenotypic analysis of cutaneous squamous cell carcinoma and intraepidermal carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not Foxp3+ regulatory t-cells is associated with disease stage. PloS Pme 2014; 9(10): e110928.

Freeman M. Predicting success and side effects with imiquimod therapy. J Am Acad Dermatol 2012 Apr; 66(4): Suppl 1, AB157. doi: 10.1016/j.jaad.2011.11.660

Freeman A, Freeman M. Ambulight an organic led automated battery operated light source compared to the Actilight for Metvix PDT. Australas J Dermatol 2012; 53.

Freeman M. Fractionated CO2 laser for congenital melanocytic naevi. Australas J Dermatol 2012; 53.

Freeman A, Freeman M. Fading away benign congenital melanocytic naevi with fractionated CO2 Laser. Australas J Dermatol 2012; 53.

Freeman AM, Freeman MG. Efficacy and safety of 35% Trichloroacetic acid vs Fraxel 1927 nm fractionated laser in the treatment of facial actinic keratoses. Australas J Dermatol 2011; 52.

Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenolmebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 2010 May; 51(2): 99-105. PMID: 20546215 / doi: 10.1111/j.1440-0960.2010.00626.x

Foley P, Freeman M, Gebauer K, Murrell D, Shumack S, Tyson C, Varigos G. Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program. Int J Dermatol 2009 Dec; 48(12): 1376-1384. PMID: 19930495  / doi: 10.1111/j.1365-4632.2009.04217.x

Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, Lowe NJ, Jarratt MT, Murrell DF, Rich P, Pariser DM, Oseroff AR, Barnetson R, Anderson C, Kossard S, Gibson LE, Tope WD. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009 Nov; 48(11): 1236-1245. PMID: 20064185 / doi: 10.1111/j.1365-4632.2008.04022.x

Holmes C, Foley P, Freeman M, Chong AH. Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas J Dermatol 2007 May; 48(2): 67-74; quiz 75-76. PMID: 17535191 / doi: 10.1111/j.1440-0960.2007.00339.x

Freeman M, Siller G, Edwards S, Amies M. Imiquimod 5% cream in the treatment of multiple superficial basal cell carcinoma. Journal of the American Academy of Dermatology 2004; 50(3): P7. doi: 10.1016/j.jaad.2003.10.03

Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, Murrell D, Anderson C, Weightman W, Reid C, Watson A, Foley P. A prospective study of the use of cryosurgery for the treatment of actinic keratosis. Int J Dermatol 2004 Sep; 43(9): 687-692. PMID: 15357755 / doi: 10.1111/j.1365-4632.2004.02056.x

Swindle LD, Thomas SG, Freeman M, Delaney PM. View of normal human skin in vivo as observed using fluorescent fiber-optic confocal microscopic imaging. J Invest Dermatol 2003 Oct; 121(4): 706-712. PMID: 14632185 / doi: 10.1046/j.1523-1747.2003.12477.x

Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003 Jun; 14(2): 99-106. PMID: 12775317  / doi: 10.1080/09546630305538

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.